Catalyst Wire Dossier Catalyst Wire Dossier

rFVIIIFc-VWF-XTEN (BIVV001)

· Bioverativ, a Sanofi company
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for rFVIIIFc-VWF-XTEN (BIVV001), covering 2019-12-02 to 2019-12-02. Get the full timeline:

Most recent: Clinical Trial Update: A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) [Phase 1, Phase 2]

See pricing